10:04:56 EDT Sun 25 Sep 2022
Enter Symbol
or Name

Login ID:

Cannabis Summary for Sept. 20, 2022

2022-09-20 20:14 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The S&P/TSX Cannabis Index lost 1.13 to 40.15, while the CSE Composite Index lost 2.29 to 269.39. South of the border, Charlie Bachtell's Cresco Labs Inc. (CL) lost seven cents to $4.19 on 140,300 shares, despite trumpeting a geographic expansion of a "multimarket-leading" eponymous brand. The Cresco vape and concentrate brand will now be available in a ninth market, Florida.

While the press release was largely an exercise in advertising the "premium quality" of a "robust" lineup, it also underlined a rising focus on Florida. Cresco first entered the state last year by buying Brady Cobb's Bluma Wellness in an all-share deal valued at $213-million (U.S.). (Unfortunately for Bluma's old shareholders, that value looks a lot lower now: The 15.8 million shares issued by Cresco are today worth just $49.6-million (U.S.).) Bluma had eight dispensaries at the time, and Cresco has since opened 11 more.

The expansion comes amid a continuing rise in demand. Just last week, Florida's registered cannabis patient count (the state is medical-only) topped three-quarters of a million people, at 751,000, according to the state regulator. That is up from 612,000 a year earlier. The analysts at Beacon Securities expect it to head higher still. In a research note yesterday, they pointed out that Florida's "patient penetration rate" (the percentage of the eligible population) is 3.5 per cent, "notably short" of a benchmark that they reckoned should be 4.3 per cent. This suggests room for many tens of thousands of additional patients.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2022 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.